Q3 2021 |
18 |
$38.5M |
+$2.44M |
-$7.66M |
-$5.22M |
GILD, GSKXXXX, PFE, ALKS, AMYT
|
13F-HR |
11/12/2021, 07:56 PM |
Q2 2021 |
18 |
$46.2M |
+$9.13M |
-$1.3M |
+$7.83M |
GILD, GSKXXXX, PFE, ALKS, BMY
|
13F-HR |
8/16/2021, 11:28 AM |
Q1 2021 |
18 |
$39.2M |
+$23.7M |
-$12.8M |
+$10.8M |
GILD, PFE, GSKXXXX, CLVSQ, VYNE
|
13F-HR |
5/17/2021, 08:27 AM |
Q4 2020 |
17 |
$29.7M |
+$2.06M |
-$2.48M |
-$419K |
ABBV, GSKXXXX, VYNEXXXX, GILD, TYME
|
13F-HR |
2/16/2021, 12:48 PM |
Q3 2020 |
18 |
$30.3M |
+$6.89M |
-$2.04M |
+$4.85M |
GSKXXXX, JAZZ, GILD, ABBV, VYNEXXXX
|
13F-HR |
11/16/2020, 08:48 AM |
Q2 2020 |
19 |
$39.2M |
+$5.29M |
-$9.48M |
-$4.19M |
GSKXXXX, GILD, SPXUXXXX, MNLO, TYME
|
13F-HR |
8/14/2020, 09:13 AM |
Q1 2020 |
26 |
$59.5M |
+$36.3M |
-$2.98M |
+$33.3M |
ABBV, GSKXXXX, GILD, GILD, SPXUXXXX
|
13F-HR |
5/15/2020, 08:47 AM |
Q4 2019 |
16 |
$34M |
+$2.6M |
-$1.12M |
+$1.48M |
GSKXXXX, GILD, ABBV, CVS, TYME
|
13F-HR |
2/14/2020, 01:02 PM |
Q3 2019 |
22 |
$55.4M |
+$29.3M |
-$7.65M |
+$21.6M |
SPY, GILD, GSKXXXX, VIXYXXXX, ABBV
|
13F-HR |
11/14/2019, 10:56 AM |
Q2 2019 |
19 |
$53.3M |
+$36.3M |
|
+$36.3M |
GILD, SPY, GSKXXXX, GILD, ABBV
|
13F-HR |
8/14/2019, 10:46 AM |
Q1 2019 |
10 |
$26M |
+$10.1M |
|
+$10.1M |
AGN, GSKXXXX, TYME, GILD, LGND
|
13F-HR |
5/14/2019, 05:09 PM |
Q4 2018 |
10 |
$25.7M |
+$1.44M |
-$507K |
+$937K |
TYME, LAB, GSKXXXX, BIS, AGN
|
13F-HR |
2/13/2019, 11:01 AM |
Q3 2018 |
12 |
$41.3M |
+$1.02M |
-$1.71M |
-$687K |
GILD, AMRN, TYME, GSKXXXX, AGN
|
13F-HR |
11/13/2018, 04:49 PM |
Q2 2018 |
13 |
$35.3M |
+$10.6M |
|
+$10.6M |
GILD, TYME, NVLNF, GSKXXXX, AGN
|
13F-HR |
8/7/2018, 04:13 PM |
Q1 2018 |
9 |
$24.1M |
+$4M |
|
+$4M |
GILD, TYME, NVLNF, LAB, GSKXXXX
|
13F-HR |
4/27/2018, 05:13 PM |
Q4 2017 |
11 |
$32.9M |
+$964K |
|
+$964K |
TYME, GILD, GILD, NVLNF, LAB
|
13F-HR |
1/23/2018, 12:05 PM |
Q3 2017 |
12 |
$49.5M |
+$16.6M |
-$252K |
+$16.4M |
TYME, PFE, NVLNF, GILD, GILD
|
13F-HR |
11/13/2017, 09:23 AM |
Q2 2017 |
17 |
$55.7M |
+$14.4M |
|
+$14.4M |
PFE, NVLNF, DEPO, GILD, BIS
|
13F-HR |
8/10/2017, 03:10 PM |
Q1 2017 |
19 |
$58.5M |
+$5.06M |
-$20.3M |
-$15.2M |
NVLNF, PFE, SPY, GILD, DEPO
|
13F-HR |
5/12/2017, 03:30 PM |
Q4 2016 |
20 |
$93.3M |
+$54.5M |
-$3.09M |
+$51.4M |
SPY, ANIP, PFE, NVLNF, DEPO
|
13F-HR |
2/10/2017, 09:53 AM |
Q3 2016 |
20 |
$63.1M |
+$7.32M |
-$14.7M |
-$7.43M |
ANIP, DEPO, PFE, DGX, AMRI
|
13F-HR |
11/10/2016, 02:02 PM |
Q2 2016 |
26 |
$82.5M |
+$18.3M |
-$4.47M |
+$13.8M |
ANIP, SPY, DEPO, PFE, DGX
|
13F-HR |
8/15/2016, 12:18 PM |
Q1 2016 |
29 |
$67.9M |
+$21.4M |
-$969K |
+$20.4M |
ANIP, AMRI, PFE, SPY, DEPO
|
13F-HR |
5/16/2016, 12:13 PM |
Q4 2015 |
22 |
$60.5M |
+$4.29M |
-$3.81M |
+$485K |
ANIP, AMRI, QLTI, PFE, DGX
|
13F-HR |
2/16/2016, 01:53 PM |
Q3 2015 |
28 |
$70.1M |
+$18.2M |
-$9.02M |
+$9.22M |
ANIP, AMRI, AZN, QLTI, PFE
|
13F-HR |
11/16/2015, 09:57 AM |
Q2 2015 |
30 |
$95.2M |
+$43.4M |
-$6.43M |
+$37M |
AMRI, QLTI, BIS, MNKDXXXX, ANIP
|
13F-HR |
8/14/2015, 09:47 AM |
Q1 2015 |
36 |
$91.8M |
+$36.8M |
-$3.27M |
+$33.6M |
AZN, AMRI, TWM, AZN, TEVA
|
13F-HR |
5/14/2015, 02:57 PM |
Q4 2014 |
26 |
$54.7M |
+$14.7M |
-$5.56M |
+$9.16M |
AMRI, AZN, TEVA, DGX, PFE
|
13F-HR |
2/13/2015, 12:13 PM |
Q3 2014 |
32 |
$104M |
+$57.3M |
-$5.64M |
+$51.6M |
TWM, AMRI, ANIP, B108PS, B108PS
|
13F-HR |
11/13/2014, 10:15 AM |
Q2 2014 |
33 |
$119M |
+$26.9M |
-$4.72M |
+$22.2M |
SPY, TWM, IWM, AMRI, AZN
|
13F-HR |
8/13/2014, 04:14 PM |
Q1 2014 |
45 |
$153M |
+$80.4M |
-$38.2M |
+$42.2M |
SPY, MDY, TWM, AMRI, AUXL
|
13F-HR |
5/13/2014, 12:24 PM |
Q4 2013 |
36 |
$136M |
|
|
|
MDY, IBB, ANIP, SPY, TEVA
|
13F-HR |
2/13/2014, 08:15 AM |